Understanding and targeting cancer persister cells
This project aims to develop tools for studying cancer persister cells using single-cell lineage tracing to enhance understanding and treatment of therapy-resistant tumors.
Projectdetails
Introduction
Despite tremendous progress in cancer therapy, many patients still succumb to the disease following an initial successful response to treatment. In addition to the long-appreciated contribution of genetically mutated cells to disease recurrence, persister cells, a rare subpopulation of cells that evade therapy in the absence of any known resistance-mediating mutation, have recently emerged as orthogonal drivers of therapy failure.
Challenges in Understanding Persister Cells
While there has been much progress in targeting genetic resistance, the paucity of molecular tools that can capture persister traits, as well as the lack of a robust methodological framework for their study, have significantly hampered our understanding and ability to target persister cells.
Opportunities for Research
Nevertheless, recent breakthroughs in molecular profiling techniques, as well as growing access to human residual disease clinical samples, now provide the opportunity to uncover the molecular underpinnings of this crucial cellular state.
Project Proposal
In this project, I propose to combine state-of-the-art single-cell lineage tracing techniques with functional approaches to:
- Identify the determinants that control the ability of persister cells to escape therapy-induced senescence.
- Elucidate the cellular processes that govern the duration of persister drug-induced arrest.
- Investigate how epigenetic memory shapes persisters’ response to subsequent cycles of therapy.
Goals of CancerPersisters
CancerPersisters will establish the tools that are needed in order to study key persister traits and further our understanding of this important cancer phenotype.
Potential Impact
Successful completion of this project may instruct the development of new classes of cancer drugs that can resensitize patients to subsequent cycles of therapy by erasing cellular memory and increase progression-free survival by modulating the duration of drug-induced arrest.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.728.750 |
Totale projectbegroting | € 1.728.750 |
Tijdlijn
Startdatum | 1-8-2024 |
Einddatum | 30-9-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- TEL AVIV UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Cancer cell plasticity on targeted therapyThis project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic RecurrenceThis project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes. | ERC Consolid... | € 1.995.582 | 2024 | Details |
Deciphering non-genetic determinants and targetability of cancer cell plasticity.This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment. | ERC Consolid... | € 2.000.000 | 2025 | Details |
What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancerThis project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations. | ERC Consolid... | € 1.999.754 | 2024 | Details |
Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapyThis project aims to develop a single-cell multiomics method to understand epigenetic resistance mechanisms in AML, enhancing treatment strategies against drug resistance. | ERC Starting... | € 1.882.440 | 2024 | Details |
Cancer cell plasticity on targeted therapy
This project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes.
Dynamics of Adaptation and Resistance in Cancer: MApping and conTrolling Transcriptional and Epigenetic Recurrence
This project aims to uncover the mechanisms of drug resistance in colorectal cancer through innovative models and computational methods, ultimately improving treatment strategies and patient outcomes.
Deciphering non-genetic determinants and targetability of cancer cell plasticity.
This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.
What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancer
This project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations.
Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy
This project aims to develop a single-cell multiomics method to understand epigenetic resistance mechanisms in AML, enhancing treatment strategies against drug resistance.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell PathwaysDevelop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes. | EIC Transition | € 2.433.125 | 2022 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways
Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.